{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:34:22Z","timestamp":1790087662026,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022336","name":"Esperion Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lipidjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jacl.2023.10.011","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:40:46Z","timestamp":1698799246000},"page":"e59-e69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9912-1408","authenticated-orcid":false,"given":"Harold E.","family":"Bays","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LeAnne T.","family":"Bloedon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1970-6361","authenticated-orcid":false,"given":"Heather A.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5464-8986","authenticated-orcid":false,"given":"Michael J.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Michael","family":"Lincoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-6464","authenticated-orcid":false,"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jacl.2023.10.011_bib0001","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamacardio.2018.2258","article-title":"Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels","volume":"3","author":"Sabatine","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"9753","key":"10.1016\/j.jacl.2023.10.011_bib0002","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170\u2008000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2023.10.011_bib0003","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"issue":"24","key":"10.1016\/j.jacl.2023.10.011_bib0004","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/ AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2023.10.011_bib0005","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National lipid association recommendations for patient-centered management of dyslipidemia: Part 1\u2014Full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"11","key":"10.1016\/j.jacl.2023.10.011_bib0006","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia","volume":"67","author":"Perez de Isla","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2023.10.011_bib0007","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","article-title":"Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries","volume":"285","author":"De Backer","year":"2019","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.jacl.2023.10.011_bib0008","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jacl.2013.09.009","article-title":"Therapeutic practice patterns related to statin potency and ezetimibe\/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease","volume":"8","author":"Toth","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2023.10.011_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2017.03.001","article-title":"Use of lipid-modifying therapy and LDL-C goal attainment in a high-cardiovascular-risk population in the Netherlands","volume":"39","author":"Kuiper","year":"2017","journal-title":"Clin Ther"},{"issue":"18","key":"10.1016\/j.jacl.2023.10.011_bib0010","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.jacc.2022.02.048","article-title":"High-intensity statin use among patients with atherosclerosis in the U.S","volume":"79","author":"Nelson","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacl.2023.10.011_bib0011","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.molmed.2017.09.001","article-title":"Targeting ATP-citrate lyase in hyperlipidemia and metabolic disorders","volume":"23","author":"Pinkosky","year":"2017","journal-title":"Trends Mol Med"},{"issue":"1","key":"10.1016\/j.jacl.2023.10.011_bib0012","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacl.2023.10.011_bib0013","unstructured":"Nexletol PRESCRIBING INFORMATION. www.fda.gov\/medwatch."},{"key":"10.1016\/j.jacl.2023.10.011_bib0014","unstructured":"Nexlizet PRESCRIBING INFORMATION. www.fda.gov\/medwatch."},{"issue":"15","key":"10.1016\/j.jacl.2023.10.011_bib0015","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jacl.2023.10.011_bib0016","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ahj.2020.10.060","article-title":"Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance","volume":"235","author":"Nicholls","year":"2021","journal-title":"Am Heart J"},{"issue":"15 (Suppl)","key":"10.1016\/j.jacl.2023.10.011_bib0017","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1016\/j.jacl.2023.10.011_bib0018","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jacl.2020.08.009","article-title":"Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials","volume":"14","author":"Bays","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"13","key":"10.1016\/j.jacl.2023.10.011_bib0019","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1161\/CIRCULATIONAHA.114.013189","article-title":"Statin intolerance","volume":"131","author":"Fitchett","year":"2015","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacl.2023.10.011_bib0020","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.jacl.2023.10.011_bib0021","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacl.2022.09.001","article-title":"Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association","volume":"17","author":"Warden","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"24","key":"10.1016\/j.jacl.2023.10.011_bib0022","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"issue":"9716","key":"10.1016\/j.jacl.2023.10.011_bib0023","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"9435","key":"10.1016\/j.jacl.2023.10.011_bib0024","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacl.2023.10.011_bib0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00125-008-1179-5","article-title":"Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial","volume":"52","author":"Holman","year":"2009","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.jacl.2023.10.011_bib0026","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3132\/dvdr.2008.029","article-title":"The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"5","author":"Newman","year":"2008","journal-title":"Diab Vasc Dis Res"},{"issue":"4","key":"10.1016\/j.jacl.2023.10.011_bib0027","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nrcardio.2012.15","article-title":"Pharmacotherapy: Statins and new-onset diabetes\u2013the important questions","volume":"9","author":"Preiss","year":"2012","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2023.10.011_bib0028","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCOUTCOMES.109.868299","article-title":"The JUPITER trial: results, controversies, and implications for prevention","volume":"2","author":"Ridker","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"21","key":"10.1016\/j.jacl.2023.10.011_bib0029","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacl.2023.10.011_bib0030","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/dom.14645","article-title":"Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials","volume":"24","author":"Leiter","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.jacl.2023.10.011_bib0031","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4103\/0975-7406.171699","article-title":"Statins and its hepatic effects: newer data, implications, and changing recommendations","volume":"8","author":"Jose","year":"2016","journal-title":"J Pharm Bioallied Sci"},{"key":"10.1016\/j.jacl.2023.10.011_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1028355","article-title":"Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome","volume":"9","author":"Biolo","year":"2022","journal-title":"Front Cardiovasc Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287423003136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287423003136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T12:49:00Z","timestamp":1710938940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287423003136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1933287423003136"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2023.10.011","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2023.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}